| Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (NCT03828201) | Boston University | 2022-06-07 |
| A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China (NCT05306223) | Beijing Chest Hospital | 2022-05-10 |
| Bioneer Q-RFIA Clinical Evaluation (NCT05117788) | Foundation for Innovative New Diagnostics, Switzerland | 2022-02-23 |
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis (NCT04179500) | Global Alliance for TB Drug Development | 2021-09-16 |
| Clinical Evaluation of tNGS for Diagnosis of DR-TB (NCT04239326) | Foundation for Innovative New Diagnostics, Switzerland | 2021-04-16 |
| PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis (NCT04783727) | Research Center Borstel | 2021-04-01 |
| Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens (NCT05871489) | Harvard Medical School (HMS and HSDM) | 2020-09-22 |
| Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (NCT03896685) | Médecins Sans Frontières, France | 2020-04-06 |
| Safety of RUTI® Vaccination in MDR-TB Patients (NCT02711735) | Archivel Farma S.L. | 2020-03-18 |
| Xpert MTB/XDR Clinical Evaluation Trial (NCT03728725) | Foundation for Innovative New Diagnostics, Switzerland | 2019-07-11 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients (NCT03338621) | Global Alliance for TB Drug Development | 2018-07-30 |
| Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients (NCT03409315) | University Medical Center Groningen | 2018-02-10 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis (NCT03086486) | Global Alliance for TB Drug Development | 2017-11-21 |
| The Individualized M(X) Drug-resistant TB Treatment Strategy Study (NCT03237182) | Centre for the AIDS Programme of Research in South Africa | 2017-06-14 |
| DIAgnostics for Multidrug Resistant Tuberculosis in Africa (NCT03303963) | Dissou AFFOLABI | 2017-05-04 |
| Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (NCT02589782) | Medecins Sans Frontieres, Netherlands | 2017-01-01 |
| Evaluating Newly Approved Drugs for Multidrug-resistant TB (NCT02754765) | Médecins Sans Frontières, France | 2016-12-01 |
| Study of TB Lesions Obtained in Therapeutical Surgery (NCT02715271) | Fundació Institut Germans Trias i Pujol | 2016-09-01 |
| Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory Concentrations (NCT02816931) | Karolinska Institutet | 2016-03-01 |
| Treatment Shortening of MDR-TB Using Existing and New Drugs (NCT02619994) | Seoul National University Hospital | 2016-01-01 |
| Nosocomial Transmission of MDR-TB in Bucharest, Romania (NCT02413931) | Research Center Borstel | 2015-05-01 |
| Expand New Drugs for TB [endTB] (NCT03259269) | Partners in Health | 2015-04-01 |
| An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (NCT02365623) | Janssen Pharmaceutical K.K. | 2015-02-18 |
| Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (NCT01918397) | Boston University | 2015-01-01 |
| Biomarkers for Therapy Response in Drug-resistant Tuberculosis (NCT02597621) | Research Center Borstel | 2013-03-01 |
| Training Protocol on the Natural History of Tuberculosis (NCT01212003) | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-06-30 |
| Tuberculosis in China (NCT01071603) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-02-02 |
| A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 (NCT02573350) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-03-26 |
| A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) (NCT00685360) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2008-05-08 |
| Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru (NCT01201941) | Brigham and Women's Hospital | 2004-11-01 |
| High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis (NCT00513396) | GSVM Medical College | 2004-01-01 |